Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by BeiGene, Ltd. < Previous 1 2 Next > BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World July 23, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer July 18, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 June 14, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL May 24, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 May 14, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Reports First Quarter 2024 Financial Results and Business Updates May 08, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report April 26, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting April 24, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer April 23, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy March 14, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma March 07, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 March 06, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia February 29, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene to Present at Upcoming Investor Conferences February 28, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA February 27, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates February 26, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer February 26, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors January 23, 2024 From BeiGene, Ltd. Via Business Wire Tickers BGNE FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL) December 22, 2023 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference December 21, 2023 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023 November 29, 2023 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023 November 28, 2023 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor November 21, 2023 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma November 17, 2023 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates November 09, 2023 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene to Present at the Jefferies London Healthcare Conference November 08, 2023 From BeiGene, Ltd. Via Business Wire Tickers BGNE BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia October 20, 2023 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC) October 17, 2023 From BeiGene, Ltd. Via Business Wire Tickers BGNE BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma October 17, 2023 From BeiGene, Ltd. Via Business Wire Tickers BGNE < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.